Reputations for Sale ? BMJ-BBC-Panorama-Seroxat/ Paxil
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
-
-
Canadian Study: SSRI Increase Bone Fracture Risk
"Daily use of SSRIs was also associated with a four per cent reduction in bone mineral density of the hip and 2.4 per cent of the lower spine, the study found."
-
YouTube Videos RE: Antidepressants
The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
-
Public Testimonies at FDA-SSRI-Suicidality Hearings, Dec. 13, 2006
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
-
Eli Lilly Documents Show Risks of Zyprexa were deliberately played down_NYT
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation." -
MEDIA ALERT: Drug Victim advocates and Expert Scientists and Physicians
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
-
Evidence of Drug Harm that the FDA Sought to Suppress
Evidence of Antidepressant Harm that the FDA Sought to Suppress from FDA’s Public Advisory Committee Meeting on February 2 Evidence was presented on February 2 at AHRP’s press briefing by the following scientists: David Healy, MD, Director of the North Wales Department of Psychological Medicine and Visiting Professor, University of…
-
Dr. David Healy Addresses Credibility Crisis-at Columbia University Oct. 20
Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…
-
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…
-
BBC Panorama: Unprecedented public response to evidence of SSRI drug harm
BBC Panorama: Unprecedented public response to evidence of SSRI drug harm Wed, 21 May 2003 In a stunning follow up to its investigative report, The Secret of Seroxat, aired October 13, 2002, the British Broadcasting Company (BBC) featured the public responses to its earlier program as the focus of its…
-
Epidemiologist Says Most Published Research Findings Are False – Psychiatrist Addresses Credibility Crisis
Epidemiologist Says Most Published Research Findings Are False – Psychiatrist Addresses Credibility Crisis Sat, 8 Oct 2005 An article published in PLoS Medical (an Open Access Peer Reviewed Medical Journal) by an epidemiologist who holds academic positions on both sides of the Atlantic–at the University of Ioannina (Greece) and Tufts…
-
Unreported Paxil suicides: company abandons "No Addiction" claim
Unreported Paxil suicides: company abandons “No Addiction” claim Sat, 10 May 2003 GlaxoSmithKline, Britain’s biggest pharmaceutical company will change the label in the UK to reflect the severe withdrawal that its antidepressant drug, Seroxat (Paxil in US) generates in many patients. In Britain, the package label will no longer claim…